CLINAPTIS RESEARCH
Browse Learn
CLINAPTIS LEARN · DRUG DEVELOPMENT

What Are IND, NDA, BLA and PDUFA Dates?

Before a medicine can be sold in the United States, the company developing it must work through a series of FDA applications. Each has a different purpose. And one date—the PDUFA action date—can become a major milestone for patients, companies and investors.

At a glance
INDPermission to begin human studies
NDA / BLARequest to market a drug
FDA reviewAssess evidence and quality
ActionApprove or identify deficiencies

Simplified pathway. Some products and application types follow different procedures.

2. What do IND, NDA, BLA and sNDA mean?

These abbreviations describe different steps in the same journey. An IND is about testing a drug in people; an NDA or BLA is about seeking permission to sell it. A supplement requests certain changes to an already approved application.

Before clinical trialsIND

Investigational New Drug application. Provides FDA with preclinical safety, manufacturing and study-plan information before a proposed clinical trial. Normally, the trial can begin after 30 days if FDA has not imposed a clinical hold, or sooner if FDA permits it.

Request for first approvalNDA

New Drug Application. Usually submitted for a small-molecule medicine. It contains clinical trial results, safety analyses, proposed labeling and manufacturing information.

Request for first approvalBLA

Biologics License Application. The marketing application used for biological products such as many therapeutic antibodies. FDA evaluates the clinical evidence and the ability to manufacture the biologic reliably.

After prior approvalsNDA / sBLA

Supplemental NDA / supplemental BLA. Requests a change to an existing approval—for example, adding a new disease indication. Not every supplement is an efficacy supplement; manufacturing and labeling changes may also require supplements.

Useful distinction: Filing an IND is not FDA approval of the medicine. Filing an NDA or BLA is not approval either. The agency must review the evidence and issue its decision.

3. How long does FDA review take?

For an original new-molecular-entity NDA or original BLA, the FDA generally has a 60-day filing review after receiving the application. If it accepts the application for review, the main PDUFA goal is usually measured from that filing date.

Standard review
10 months

FDA's goal to act on a filed original NME NDA or BLA.

Priority review
6 months

FDA's goal for qualifying filed applications; not a lower evidence standard.

Illustrative timeline · NME NDA / original BLA
Day 0Company submits
~Day 60FDA filing decision
+6 or +10 monthsTarget FDA action

These are review goals, not promises. For non-NME NDAs and certain supplements, the goal typically runs from FDA receipt rather than the 60-day filing date. [5, 6]

For efficacy supplements such as applications for a new indication, typical goals are also 10 months for standard review and 6 months for priority review, generally measured from receipt. Other kinds of supplements have different timelines. [5]

4. What is a PDUFA action date?

The PDUFA action date is FDA's target date to act on a drug application under goals associated with the Prescription Drug User Fee Act. The date helps the company plan and gives patients and investors a point on the calendar to watch.

PDUFA date ≠ guaranteed approval date. FDA may approve the medicine, issue a Complete Response Letter explaining why it cannot approve the application in its present form, or change the review timeline. An action can also occur before the target date. [7, 8]

Imagine a biotech reports a December 15 PDUFA date. It means FDA plans to take an action by that date—not that the medicine will necessarily be available on December 15.

5. What decisions can FDA make?

ApprovalThe drug can be marketed

FDA concludes the application supports approval for the specified use, subject to approved labeling and any required risk controls or follow-up commitments.

Complete Response Letter · CRLNot approved yet

FDA has completed its review but cannot approve the application in its present form. The letter explains deficiencies that must be addressed before approval is possible.

A CRL does not always mean the drug failed its clinical trial. The problem could involve uncertain effectiveness, safety, missing analyses or manufacturing deficiencies. What matters is what FDA requires to fix it. [8]

6. What can go wrong during FDA review?

An encouraging Phase 3 result is important, but it is not the entire application. FDA examines evidence, patient safety, production quality and proposed labeling. Problems can lead to requests for more information, a review delay or a CRL.

IssueWhat it means in plain English
More analysesFDA may ask the sponsor to re-check results, investigate missing data or clarify safety findings.
More clinical evidenceFDA may conclude effectiveness has not been established and request an additional adequate and well-controlled study, potentially a randomized controlled trial.
Safety / toxicologySafety findings in patients or nonclinical studies may leave unanswered questions about risks.
REMSA Risk Evaluation and Mitigation Strategy may be needed to manage a serious risk; it can involve special monitoring, training or restricted distribution.
CMC / manufacturingChemistry, Manufacturing and Controls questions may involve purity, stability, consistent batches, quality systems or plant inspections—even if the clinical trial succeeds.
Major amendmentSubstantial new information submitted during review can extend the PDUFA goal date, commonly by three months for a qualifying major amendment.
Two very different problems
Clinical evidence gap

If FDA requires a new trial, the sponsor may need to enroll and follow patients for months or years.

Manufacturing gap

If a factory or quality-control issue can be corrected, the sponsor may resolve it without repeating the pivotal clinical study.

Neither category guarantees a quick fix. The size of the problem—not just the word “CRL”—determines the next step.

7. What happens after a delay or rejection?

The sponsor usually works with FDA to understand the deficiencies and decides how to respond. A company may submit corrected manufacturing information, revise its risk-management plan, provide new analyses or run another clinical trial. After a CRL, it may resubmit the application; the review goal for many Class 1 resubmissions is 2 months, while Class 2 resubmissions generally have a 6-month goal. Those clocks begin with FDA receipt of the resubmission, not the original application. [5, 8]

The one point to remember

A PDUFA date is a decision milestone, not a promise of approval. Always ask whether FDA's unresolved questions concern clinical benefit, safety, manufacturing or simply additional documentation.

References and further reading

Primary FDA and US regulatory resources. Review goals shown reflect the PDUFA VII framework (FY 2023–2027).

  1. FDA — IND applications overview
  2. FDA — IND clinical holds
  3. FDA — The drug review process
  4. FDA — BLAs for CBER-regulated products
  5. FDA — PDUFA VII goals, FY 2023–2027
  6. FDA — Priority Review
  7. FDA — Review timeline and sponsor communications
  8. 21 CFR §314.110 — Complete response letters
  9. FDA — REMS
  10. FDA — Chemistry, Manufacturing and Controls

Continue learning

Applications and review dates sit between clinical evidence and market access. These guides cover the steps on either side.

Educational content, not investment advice. Terms